It would just be nice to have one positive for one its been years since we had one. Been painful to watch and given there will basically be no revenue in Europe for a year Brave is all we really got right now. This stock will either sit below a buck for the next year or it will shoot up with Brave.
Wouldn’t the generics just eat our lunch on any uptick in sales as a result of positive Brave outcomes? And regarding huge opportunity with respect to preventing Alzheimer’s - we already have a drug that prevents debilitating strokes and heart attacks and guess what - nobody appears to want to pay for preventative drugs, unfortunately.
Market Data 
Markets 
AI
